In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

Patronus AI unveiled “Generative Simulators,” adaptive “practice worlds” that replace static benchmarks with dynamic ...

You tell it to clean up a deployment, and it might literally delete a production environment because it doesn’t understand intent the way a human does.” He adds: “This excessive agency problem is ...

The MM+M editorial team was heartened by the progress made treating Alzheimer’s disease, the case of KJ Muldoon and ...

Skills—a capability that allows users to teach Claude repeatable workflows—was introduced in October, and now Anthropic is ...

For many, the festive season conjures images of cosy gatherings, twinkling lights and joyful celebration. But beneath the ...

The lack of gains in productivity from AI could stall adoption and burst the economic bubble. Is there a rational explanation ...

Primary school students have been reading TikTok sensation Icebreaker, an enemies-to-lovers romance about a figure skater and ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...